advertisement
Abstract #6467 Published in IGR 3-2
The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KEAmerican Journal of Ophthalmology 2001; 131: 631-635
PURPOSE: To evaluate the efficacy and safety of latanoprost 0.005% given topically every evening versus brimonidine 0.2% given topically twice daily in primary open-angle glaucoma (POAG) or ocular hypertensive patients. METHODS: This was a multicenter, crossover, double-masked comparison. After a 28-day treatment-free period, patients with POAG or ocular hypertension were randomized for six weeks to brimonidine or latanoprost, and then crossed over to the opposite treatment. At baseline and after each treatment period, patients underwent intraocular pressure (IOP) measurement every two hours from 08.00 to 20.00. RESULTS: In 33 patients, the mean baseline trough (08.00) was 23.2 ± 2.1 mmHg, and the diurnal curve pressure 19.8 >PLM> 2.7 mmHg. The trough and diurnal IOPs for brimonidine were 19.6 ,PLM> 3.4 and 17.6 ± 2.2 mmHg, respectively. Brimonidine statistically reduced the pressure from baseline at each time point, except for hours 10 and 12 (p = 0.14 and 0.21, respectively). For latanoprost, the trough and diurnal pressures were 16.2 ± 2.9 and 15.4 ± 2.5 mmHg, respectively, and the pressure was statistically reduced at each time point (p < 0.001) and for the diurnal curve (p < 0.001). When compared directly, the IOP level for latanoprost was lower than brimonidine for the diurnal pressure and at each time point (p < 0.05). One patient was discontinued early from latanoprost treatment because of eyelid swelling; also, latanoprost caused more hyperemia than brimonidine (p = 0.04). CONCLUSIONS: This study suggests that latanoprost dosed daily in the evening statistically reduces IOP more during daytime and evening hours than brimonidine dosed twice daily. Brimonidine may not consistently decrease the pressure at ten and 12 hours past dosing from nontreated levels.
Dr W.C. Stewart, Pharmaceutical Research Corporation, 1639 Tatum Street, Charleston, SC 29412-2464, USA
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
